Live data · NADAC + Part D CY24 · reviewed daily

Oxaprozin (COXANTO)

Nonsteroidal Anti-inflammatory Drug class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval1992-10-29
Generic availableYes · 4 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.7M in CY2024 Part D spend23K claims · 8K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.475/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.501
Across all dosage forms in distribution.
Highest NADAC
$0.603
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Oxaprozin used for?

Oxaprozin is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Oxaprozin?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Oxaprozin?

Across 329 Part D plans, Oxaprozin averages $0.501/unit (NADAC). Lowest available: $0.475/unit. Highest in distribution: $0.603/unit.

Is Oxaprozin on the FDA shortage list?

Oxaprozin has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.